Conference Calendar - The 88th EAS Congress

All times are in CET (Central European Time)

Displaying One Session

View

Industry Sponsored Session

Not included in the main CME-CPD of the event

Session Type

Industry Sponsored Session

Room

Industry session hall

Date

07.10.2020, Wednesday

Session Time

14:30 - 16:00

Session Ticket

Session Evaluation

Please enter to our survey here

Session Evaluation

Option 1

Watch Stream
Session Webcast

Session Webcast

[{"name":"Lessons from the DA VINCI study","mode":"playlist","public":true,"info":{"id":1744,"presentation":"Lessons from the DA VINCI study","session":"Not included in the main CME-CPD of the event","presenter":"Kausik K. Ray, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/1332.jpg"},"playlist":[{"name":"Lessons","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/02_RAY_P-Q-A_v03-200_ST.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/111\/02_RAY_P-Q-A_v03-200_ST.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/7C46EC7F.jpg","data":[],"tracks":[]}]},{"name":"PCSK9 inhibition: what do we know so far?","mode":"playlist","public":true,"info":{"id":1745,"presentation":"PCSK9 inhibition: what do we know so far?","session":"Not included in the main CME-CPD of the event","presenter":"Chris Packard, United Kingdom","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/5270.jpg"},"playlist":[{"name":"PCSK9 inhibition: what do we know so far?","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/Chris Packard EAS20 PCSK9 inhibition what do we know so far.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/111\/Chris Packard EAS20 PCSK9 inhibition what do we know so far.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/64D890AC.jpg","data":[],"tracks":[]}]},{"name":"LDL-C reduction: earlier, lower, better!","mode":"playlist","public":true,"info":{"id":1746,"presentation":"LDL-C reduction: earlier, lower, better!","session":"Not included in the main CME-CPD of the event","presenter":"Fran\u00e7ois Mach, Switzerland","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/99.jpg"},"playlist":[{"name":"LDL-C reduction: earlier, lower, better!","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/Francois Mach EAS20 LDL C reduction earlier, lower, better.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/111\/Francois Mach EAS20 LDL C reduction earlier, lower, better.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/941083.jpg","data":[],"tracks":[]}]},{"name":"How did the ESC\/EAS guidelines change my practice?","mode":"playlist","public":true,"info":{"id":1747,"presentation":"How did the ESC\/EAS guidelines change my practice?","session":"Not included in the main CME-CPD of the event","presenter":"Ulrich Laufs, Germany","photo":""},"playlist":[{"name":"How did the ESCEAS guidelines change my practice","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/Laufs EAS20 How did the ESCEAS guidelines change my practice.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/111\/Laufs EAS20 How did the ESCEAS guidelines change my practice.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/AF47C85.jpg","data":[],"tracks":[]}]},{"name":"PCSK9 inhibitors; what can we learn from 5 years of real-world experience?","mode":"playlist","public":true,"info":{"id":1748,"presentation":"PCSK9 inhibitors; what can we learn from 5 years of real-world experience?","session":"Not included in the main CME-CPD of the event","presenter":"Kausik K. Ray, United Kingdom, Pasquale P. Filardi, Italy","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/1332.jpg"},"playlist":[{"name":"PCSK9 inhibitors what can we learn from 5 years of real-world experience","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/Ray And Filardi EAS20 PCSK9 inhibitors what can we learn from 5 years of real-world experience.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/111\/Ray And Filardi EAS20 PCSK9 inhibitors what can we learn from 5 years of real-world experience.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/50459271.jpg","data":[],"tracks":[]}]},{"name":"LIVE Panel discussion: with a focus on very-high risk patients","mode":"playlist","public":true,"info":{"id":1749,"presentation":"LIVE Panel discussion: with a focus on very-high risk patients","session":"Not included in the main CME-CPD of the event","presenter":"Fran\u00e7ois Mach, Switzerland, Kausik K. Ray, United Kingdom, Chris Packard, United Kingdom, Ulrich Laufs, Germany, Pasquale P. Filardi, Italy","photo":"https:\/\/cslide.ctimeetingtech.com\/global_storage\/media\/content\/eas20\/persons\/photos\/99.jpg"},"playlist":[{"name":"","source":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/Targeting PCSK9.mp4","source_path":"s3:\/\/eu-cslide-prod-recordings\/eas20\/111\/Targeting PCSK9.mp4","cover":"https:\/\/s3.eu-central-1.amazonaws.com\/eu-cslide-prod-recordings\/eas20\/111\/4F94738A.jpg","data":[],"tracks":[]}]}]